Last reviewed · How we verify
NCT05733806: MITO9B
Study on Gynecological Rare Cancers
trial testing chemotherapy, surgery in Gynecologic Cancer in 500 participants. Currently enrolling.
1 January 2025
Quick facts
| Lead sponsor | National Cancer Institute, Naples |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 500 |
| Start date | 14 October 2019 |
| Primary completion | 1 January 2025 |
| Estimated completion | 1 February 2030 |
| Sites | 2 locations across Italy |
Drugs / interventions tested
- chemotherapy, surgery
Conditions studied
- Gynecologic Cancer — all drugs for Gynecologic Cancer →
Sponsor
National Cancer Institute, Naples
Who can join
Eligibility, female only, with Gynecologic Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective, observational, multicenter study on gynecological rare tumors.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05733806
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gynecologic Cancer
Currently open trials in the same condition.
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07408349 — Guided Imagery of the Gynecological Cancer · NA · recruiting
- NCT07447050 — Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial · Phase 2 · recruiting
- NCT07173101 — Clinical Investigation of the Effects of Semiconductor Embedded Therapeutic Garments on Cancer-related Cognitive Impairm · Phase 2 · recruiting
- NCT07166042 — Guided Meditation During Radiation Therapy for Breast and Gynecological Malignancies · Phase 3 · recruiting
Other National Cancer Institute, Naples trials
Trials by the same sponsor.
- NCT07459920 — Cannabis extrAct in Oncology Patients for the Treatment of TUmor Related Symptom Burden · Phase 2 · not yet recruiting
- NCT07302451 — REDI-CaP(Recovery of Erectile Dysfunction Induced in Prostate Cancer Patients) · Phase 2 · active not recruiting
- NCT06714357 — ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer · Phase 2 · recruiting
- NCT06886282 — Spatial RadiomIcs and TRanscriptomics to the DIscovery of the Cross-link Between Colon Cancer and ChrOnic Kidney Disease · recruiting
- NCT06887244 — Effectiveness of Nurse Tele-consultation on the Quality of Elective Colonoscopy, Procedure-related Anxiety, and Financia · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05733806 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Cancer Institute, Naples
- Last refreshed: 23 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05733806.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing